Background A large proportion of the patients with cancer do not respond to
immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic …

The genetic transfer of T-cell receptors (TCRs) directed toward target antigens into T
lymphocytes has been used to generate antitumor T cells efficiently without the need for the …

Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs)
underline their impressive therapeutic potential but also their risk of severe side effects …

There are limited reports that baseline peripheral absolute neutrophil count (ANC), absolute
monocyte count (AMC), absolute lymphocyte count (ALC) and serum β2‐microglobulin level …

Chimeric antigen receptor (CAR)-T cells have enormous potentials for clinical therapies. The
CAR-T therapy has been approved for treating hematological malignancies. However, their …

Despite advanced understanding of its biology and improvements in standard of care
treatment, the outcome for children with neuroblastoma (NB), the most common solid …

Over the past decade, there have been significant advances in our understanding of the
pathogenesis of chronic lymphocytic leukemia (CLL), which has been accompanied by an …

Simple Summary The outcome of patients with locally advanced head and neck squamous
cell carcinoma (HNSCC) has not changed for the past decade despite advances in …

Prostate cancer (PCa) is the most common noncutaneous cancer diagnosis and the second
leading cause of cancer-related deaths among men in the United States. Effective treatment …

Hematological malignancies remain incurable diseases because of the high risk of relapse,
even after complete remission. Adoptive T-cell therapy (ACT) using modified T cells with …